Europe Leukapheresis Market

The Europe leukapheresis market is estimated to be worth USD 24.2 million in 2026 and USD 34.1 million by 2031, growing at a CAGR of 7.1% from 2026 to 2031.

The Europe leukapheresis market witnesses steady growth due to the increasing prevalence of leukemia and the extension of leukapheresis technology in cell and gene therapy processes. The supportive infrastructure in hospitals, an influx of CAR-T trials, and an enabling environment in Western Europe are majorly contributors to the regional market growth. The escalating need for standardized and GMP-compliant cell collection and repetitive usage of single-use disposables further helps in promoting steady market growth in this region.

To know about the assumptions considered for the study download the pdf brochure

Major players in the Europe leukapheresis market include Fresenius Kabi (Germany), Terumo BCT (Japan), Haemonetics Corporation (US), Grifols S.A. (Spain), Macopharma (France), Medica S.p.A. (Italy), Miltenyi Biotec (Germany), Baxter International Inc. (US), Nikkiso Co., Ltd. (Japan), Immune Therapy Holdings AB (Sweden), SCTbio (Czech Republic), Biohope Scientific SL (Spain), and Caltag Medsystems Ltd. (UK). These companies have adopted business expansions, product launches/developments, and other growth strategies to strengthen their presence in the market.

For instance, in April 2023, Fresenius Kabi, Germany, upgraded its Amicus Blue  Extracorporeal Photopheresis (ECP) by improving the software versions, along with the single-use, flexible, disposable kits. This improves the efficiency of the process for the procedures of leukapheresis and photopheresis.

Fresenius Kabi (Germany)

Fresenius Kabi is a major participant in the European leukapheresis market. This can largely be attributed to its extensive network of hospital collaborations and its diversified range of apheresis products. The company’s products comprise its leukapheresis systems and single-use devices. These are largely preferred by European hematology and oncology treatment facilities and transfusion stations. Its emphasis on system development and European regulations will serve it well in therapeutic leukapheresis as well as cell and gene therapies.

Terumo BCT (Japan)

Terumo BCT has a strong foothold in Europe on account of its advanced continuous flow apheresis system and also penetration in blood centers and hospitals. The company is an essential part of supporting leukapheresis for therapeutic purposes and also immune cell harvest for the purpose of cell and gene therapy. Its continued focus on training initiatives and collaboration efforts, along with CGT manufacturers in Europe, gives it strong growth potential in this market.

Market Ranking

The Europe leukapheresis market is a moderately consolidated market, which is largely occupied by the following market players: Fresenius Kabi, Terumo BCT, Haemonetics, Macopharma, and Grifols. Fresenius Kabi, along with Terumo BCT, holds a strong market position due to its installed base in hospitals and blood centers. Key market players, including Fresenius Kabi, Terumo BCT, Haemonetics, Macopharma, and Grifols, are adopting strategies such as improving products continuously, adding products including single-use disposables, and collaborations with cell and gene therapy innovators, among others.

Related Reports:

Europe Leukapheresis Market by Product (Devices, Disposable, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com